“…The persistently high excretion of this metabolite has been linked to a group of disorders characterized by defects located at the mitochondrial membrane. An increasing number of disease‐causing mutations in genes encoding for proteins related to the mitochondrial membrane have been reported in patients with 3‐methylglutaconic aciduria (3‐MGA‐uria), including: TAZ (MIM# 300394; Barth et al, ; Bione et al, ), OPA3 (MIM# 606580; Anikster, Kleta, Shaag, Gahl, & Elpeleg, ), DNAJC19 (MIM# 608977; Davey et al, ), ATPAF2 (MIM# 608918; De Meirleir et al, ), TMEM70 (MIM# 612418; Cízková et al, ), ATP5F1E (MIM# 606153; Mayr et al, ), SERAC1 (MIM# 614725; Wortmann et al, ), AGK (MIM# 610345; Aldahmesh, Khan, Mohamed, Alghamdi, & Alkuraya, ; Mayr et al, ), CLPB (MIM# 616254; Capo‐Chichi et al, ; Kanabus et al, ; Saunders et al, ; Wortmann et al, ), HTRA2 (MIM# 606441; Mandel et al, ), QIL1 (MIM# 616658; Guarani et al, ; Zeharia et al, ), TIMM50 (MIM# 607381; Shahrour et al, ), and ATP5F1D (MIM# 603150; Oláhová et al, ). Disorders associated to 3‐MGA‐uria are usually linked to variable mitochondrial respiratory chain defects and abnormal mitochondrial morphology.…”